These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36520346)

  • 1. Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma.
    Lu J; Wang H; Cao W; Chen D; He Z; Xu J
    Hum Cell; 2023 Mar; 36(2):712-724. PubMed ID: 36520346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma.
    Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K
    Front Immunol; 2021; 12():800268. PubMed ID: 34956238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Survival Signature of 5-Methylcytosine Regulators Related Long Non-Coding RNA in Hepatocellular Carcinoma.
    Pan Q; Yi C; Zhang Y
    Front Oncol; 2022; 12():884377. PubMed ID: 35686101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
    Xiao Y; Li J; Wu J
    BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
    Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
    BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of m5C-Related lncRNAs in the prognosis and immune landscape of hepatocellular carcinoma.
    Lu Q; Liu L; Wang S; Zhang Q; Li L
    Front Genet; 2022; 13():990594. PubMed ID: 36339006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.
    Li D; Li K; Zhang W; Yang KW; Mu DA; Jiang GJ; Shi RS; Ke D
    Front Immunol; 2022; 13():918140. PubMed ID: 35833147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
    Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
    BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m6A- and m5C- modified lncRNAs orchestrate the prognosis in cutaneous melanoma and m6A- modified LINC00893 regulates cutaneous melanoma cell metastasis.
    Shi HZ; Tian CC; Wu MY; Ma L; Sun JF; Chen H
    Skin Res Technol; 2024 Jul; 30(7):e13842. PubMed ID: 38965799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

  • 11. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
    Wu ZY; Shi ZY
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
    Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
    BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the expression and prognostic significance of m
    Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
    Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of m6A/m5C-related lncRNA signature for prediction of prognosis and immunotherapy efficacy in esophageal squamous cell carcinoma.
    Wang J; Ren H; Xu C; Yu B; Cai Y; Wang J; Ni X
    Sci Rep; 2024 Apr; 14(1):8238. PubMed ID: 38589454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma.
    Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z
    Front Genet; 2022; 13():903117. PubMed ID: 35692827
    [No Abstract]   [Full Text] [Related]  

  • 17. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
    Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
    Front Immunol; 2021; 12():719175. PubMed ID: 34603293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
    Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
    Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
    BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.